ZEO ScientifiX

ZEO ScientifiX FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of ZEO ScientifiX (ZEOX) as of Nov 2, 2026 is 13.42 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 30.82 % — a change of -56.45% (lower).

FCF Conversion

13.42 %

YoY

-56.45%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of ZEO ScientifiX is 2025 13.42 % . FCF Conversion Rate (FCF/EBITDA) of ZEO ScientifiX was 2024 30.82 % . It decreases by -56.45% lower compared to the previous year.

The ZEO ScientifiX FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2017
10.33 USD
Jan 1, 2018
14.92 USD
Jan 1, 2020
15.51 USD
Jan 1, 2021
24.34 USD
Jan 1, 2022
44.86 USD
Jan 1, 2023
31.82 USD
Jan 1, 2024
30.82 USD
Jan 1, 2025
13.42 USD
The ZEO ScientifiX FCF Conversion history
YEARFCF ConversionYoY
13.42 %-56.45%
30.82 %-3.14%
31.82 %-29.07%
44.86 %+84.28%
24.34 %+56.97%
15.51 %+3.92%
14.92 %+44.48%
10.33 %-77.47%
45.84 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ZEO ScientifiX Stock analysis

What does ZEO ScientifiX do? Organicell Regenerative Medicine Inc generates revenue through its clinical-stage biopharmaceutical products, primarily focusing on regenerative medicine solutions. The company's leading product, Zofin (Organicell Flow), is an acellular biologic therapeutic derived from perinatal sources, containing over 300 growth factors, cytokines, chemokines, and 102 unique microRNAs. This product is administered through doctors and clinics in the healthcare industry, targeting degenerative diseases. The company has secured FDA approvals including IND and eIND, along with IRB authorizations, enabling its therapeutic applications. The company operates within the biotechnology sector, developing biological therapeutics for degenerative conditions. Zofin (Organicell Flow) serves as the core product, leveraging natural microRNAs and exosomes from perinatal tissues without additional substances. Healthcare providers and clinics are the primary buyers of this therapeutic, utilizing it for patient treatments under FDA-approved protocols. The product's unique composition supports its application in regenerative medicine, differentiating it in the market. Organicell Regenerative Medicine Inc's business model centers on the development and commercialization of Zofin (Organicell Flow), which is used in clinical settings for degenerative disease treatment. The company's focus on FDA-approved pathways through IND and eIND approvals ensures regulatory compliance for its product distribution. Healthcare professionals and clinics are the key segments purchasing the product, driven by its therapeutic benefits and natural composition derived from perinatal sources. ZEO ScientifiX is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ZEO ScientifiX stock

FCF Conversion Rate (FCF/EBITDA) of ZEO ScientifiX is 13.42 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of ZEO ScientifiX changed from 30.82 % to 13.42 %, representing a -56.45% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) ZEO ScientifiX since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s ZEO ScientifiX with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — ZEO ScientifiX

All Key Metrics — ZEO ScientifiX